<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>A1 Diagnosis: Complete 5-Year Execution Roadmap</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, 'Helvetica Neue', Arial, sans-serif;
            line-height: 1.6;
            color: #1f2937;
            background: #f9fafb;
            padding: 40px 20px;
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            background: white;
            padding: 60px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
            border-radius: 12px;
        }

        .header {
            text-align: center;
            margin-bottom: 60px;
            padding-bottom: 40px;
            border-bottom: 3px solid #0ea5e9;
        }

        .header h1 {
            font-size: 42px;
            color: #0f172a;
            margin-bottom: 15px;
            font-weight: 800;
        }

        .header .subtitle {
            font-size: 20px;
            color: #64748b;
            font-weight: 500;
        }

        .header .tagline {
            font-size: 16px;
            color: #0ea5e9;
            margin-top: 10px;
            font-weight: 600;
        }

        .toc {
            background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%);
            padding: 30px;
            border-radius: 10px;
            margin-bottom: 50px;
            border-left: 5px solid #0ea5e9;
        }

        .toc h2 {
            color: #0c4a6e;
            margin-bottom: 20px;
            font-size: 24px;
        }

        .toc ol {
            margin-left: 20px;
        }

        .toc li {
            margin: 10px 0;
            color: #0369a1;
            font-weight: 600;
        }

        .section {
            margin-bottom: 60px;
        }

        .section h2 {
            font-size: 32px;
            color: #0ea5e9;
            margin-bottom: 25px;
            padding-bottom: 15px;
            border-bottom: 2px solid #e0f2fe;
            font-weight: 700;
        }

        .section h3 {
            font-size: 24px;
            color: #0c4a6e;
            margin-top: 30px;
            margin-bottom: 20px;
            font-weight: 700;
        }

        .section h4 {
            font-size: 18px;
            color: #0369a1;
            margin-top: 25px;
            margin-bottom: 15px;
            font-weight: 600;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            margin: 25px 0;
            font-size: 14px;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        th {
            background: linear-gradient(135deg, #0ea5e9 0%, #0284c7 100%);
            color: white;
            padding: 14px 12px;
            text-align: left;
            font-weight: 600;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }

        td {
            padding: 12px;
            border-bottom: 1px solid #e2e8f0;
            vertical-align: top;
        }

        tr:nth-child(even) {
            background-color: #f8fafc;
        }

        tr:hover {
            background-color: #f0f9ff;
        }

        .highlight-box {
            background: linear-gradient(135deg, #dbeafe 0%, #bfdbfe 100%);
            padding: 25px;
            border-radius: 10px;
            margin: 25px 0;
            border-left: 5px solid #3b82f6;
        }

        .highlight-box h4 {
            color: #1e40af;
            margin-top: 0;
        }

        .success-box {
            background: linear-gradient(135deg, #d1fae5 0%, #a7f3d0 100%);
            padding: 25px;
            border-radius: 10px;
            margin: 25px 0;
            border-left: 5px solid #10b981;
        }

        .success-box h4 {
            color: #065f46;
            margin-top: 0;
        }

        .warning-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%);
            padding: 25px;
            border-radius: 10px;
            margin: 25px 0;
            border-left: 5px solid #f59e0b;
        }

        .warning-box h4 {
            color: #92400e;
            margin-top: 0;
        }

        ul {
            margin-left: 25px;
            margin-bottom: 20px;
        }

        li {
            margin: 8px 0;
        }

        strong {
            color: #0f172a;
            font-weight: 700;
        }

        .metric {
            background: #f1f5f9;
            padding: 4px 10px;
            border-radius: 6px;
            font-weight: 600;
            color: #334155;
        }

        .stat-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin: 30px 0;
        }

        .stat-card {
            background: white;
            border: 2px solid #e0f2fe;
            border-radius: 10px;
            padding: 25px;
            text-align: center;
            transition: all 0.3s;
        }

        .stat-card:hover {
            border-color: #0ea5e9;
            box-shadow: 0 8px 20px rgba(14, 165, 233, 0.15);
            transform: translateY(-2px);
        }

        .stat-value {
            font-size: 36px;
            font-weight: 800;
            color: #0ea5e9;
            margin-bottom: 10px;
        }

        .stat-label {
            font-size: 14px;
            color: #64748b;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }

        .footer {
            margin-top: 80px;
            padding-top: 40px;
            border-top: 2px solid #e2e8f0;
            text-align: center;
            color: #64748b;
            font-size: 14px;
        }

        @media print {
            body {
                background: white;
                padding: 0;
            }
            .container {
                box-shadow: none;
                padding: 40px;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>A1 Diagnosis</h1>
            <div class="subtitle">Complete 5-Year Execution Roadmap</div>
            <div class="tagline">From 1,500 Tests to 1.5 Million: The Detailed Plan</div>
        </div>

        <div class="toc">
            <h2>ðŸ“‹ Table of Contents</h2>
            <ol>
                <li>Go-to-Market Strategy (Year by Year)</li>
                <li>Physician Adoption Model: The Math</li>
                <li>Sales & Marketing Infrastructure Build</li>
                <li>Reimbursement Strategy Timeline</li>
                <li>Operational Scaling Plan</li>
                <li>Key Milestones & Success Metrics</li>
                <li>Capital Requirements & Cash Flow</li>
            </ol>
        </div>

        <div class="success-box">
            <h4>Executive Summary: How We Reach the Projections</h4>
            <p><strong>The Question:</strong> "How do you get from 1,500 tests to 1.5 million tests in 5 years?"</p>
            <p style="margin-top: 15px;"><strong>The Answer:</strong></p>
            <p style="margin-top: 10px;"><strong>Year 1 (30,000 tests):</strong> Founder-led sales to 470 physicians at 95 practices across 5 states. MolDX Medicare coverage achieved by Month 6-9. Revenue: $7.5M.</p>
            <p><strong>Year 2 (149,000 tests):</strong> Coverage cascade drives adoption. 5 territory managers reach 2,320 physicians across 17 states. Revenue: $37.3M.</p>
            <p><strong>Year 3 (448,000 tests):</strong> Mainstream adoption. 15 territory managers reach 6,940 physicians across 35 states. Revenue: $112.0M.</p>
            <p><strong>Year 4 (940,000 tests):</strong> National coverage, 13,200 ordering physicians. Revenue: $235.0M.</p>
            <p><strong>Year 5 (1,520,000 tests):</strong> Category leadership. 20,700 physicians across 50 states. Revenue: $380.0M.</p>
            <p style="margin-top: 15px;"><strong>Total 5-Year Revenue:</strong> $772M (base case), $836M (accelerated case)</p>
            <p><strong>Capital Required:</strong> $1.68M (Phase 1), $4.2M (Phase 2), $8.5M (Phase 3)</p>
            <p><strong>Cash-Flow Positive:</strong> Within 6-9 months of launch</p>
        </div>

        <!-- Section 1: Go-to-Market Strategy -->
        <div class="section">
            <h2>1. Go-to-Market Strategy: Year by Year</h2>

            <h3>Year 1 (2027): Foundation Building â€” 30,000 Tests</h3>

            <div class="highlight-box">
                <h4>Strategic Phase: "Prove and Publish"</h4>
                <p>The Year 1 objective is not to maximize volume. It is to build the clinical evidence base that unlocks reimbursement, physician trust, and scalable growth. Every Year 1 activity serves Year 2-5 acceleration.</p>
            </div>

            <h4>Target Physician Segments</h4>
            <table>
                <thead>
                    <tr>
                        <th>Segment</th>
                        <th># Practices</th>
                        <th># Physicians</th>
                        <th>Tests/Physician/Year</th>
                        <th>Total Tests</th>
                        <th>Priority</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Academic Retina Centers</td>
                        <td>15</td>
                        <td>60</td>
                        <td>120</td>
                        <td>7,200</td>
                        <td><strong>Highest</strong></td>
                    </tr>
                    <tr>
                        <td>Large Retina Practices (5+ MDs)</td>
                        <td>25</td>
                        <td>125</td>
                        <td>80</td>
                        <td>10,000</td>
                        <td><strong>High</strong></td>
                    </tr>
                    <tr>
                        <td>Ophthalmology Groups (3+ MDs)</td>
                        <td>30</td>
                        <td>90</td>
                        <td>50</td>
                        <td>4,500</td>
                        <td>Medium</td>
                    </tr>
                    <tr>
                        <td>Progressive Primary Care Networks</td>
                        <td>10</td>
                        <td>150</td>
                        <td>35</td>
                        <td>5,250</td>
                        <td>Medium</td>
                    </tr>
                    <tr>
                        <td>Concierge/Executive Health</td>
                        <td>15</td>
                        <td>45</td>
                        <td>70</td>
                        <td>3,150</td>
                        <td>Medium</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total</strong></td>
                        <td><strong>95</strong></td>
                        <td><strong>470</strong></td>
                        <td><strong>64 avg</strong></td>
                        <td><strong>30,100</strong></td>
                        <td></td>
                    </tr>
                </tbody>
            </table>

            <h4>Why This Segmentation</h4>
            <p>Academic retina centers are the highest priority not because they generate the most volume, but because they generate the most valuable volume. A published study from Johns Hopkins, Bascom Palmer, or Wills Eye carries more weight with payers and physicians than 10,000 tests at a community practice.</p>
            <p style="margin-top: 15px;">Large retina practices are the volume engine of Year 1. These are groups of 5+ retina specialists seeing high volumes of AMD patients daily. They already manage AMD patients and understand the clinical need for earlier detection.</p>
            <p style="margin-top: 15px;">Primary care networks are included as early pilots to test the primary care distribution thesis before committing significant sales resources in Year 2.</p>

            <h4>Geographic Focus (Year 1)</h4>
            <table>
                <thead>
                    <tr>
                        <th>Market</th>
                        <th>Why</th>
                        <th>Target Practices</th>
                        <th>Est. Tests</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>California</strong></td>
                        <td>UC Irvine home base; highest AMD prevalence state</td>
                        <td>25</td>
                        <td>8,000</td>
                    </tr>
                    <tr>
                        <td><strong>Florida</strong></td>
                        <td>#2 AMD prevalence; concentrated retirement population</td>
                        <td>20</td>
                        <td>7,000</td>
                    </tr>
                    <tr>
                        <td><strong>New York/New Jersey</strong></td>
                        <td>Major academic centers (Columbia, NYU, Wills Eye)</td>
                        <td>20</td>
                        <td>6,500</td>
                    </tr>
                    <tr>
                        <td><strong>Texas</strong></td>
                        <td>Large population; major medical centers (Baylor, UT Southwestern)</td>
                        <td>15</td>
                        <td>4,500</td>
                    </tr>
                    <tr>
                        <td><strong>Massachusetts</strong></td>
                        <td>Mass Eye and Ear (AMD research leader)</td>
                        <td>15</td>
                        <td>4,000</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total</strong></td>
                        <td>5 states (38% of US population 55+)</td>
                        <td><strong>95</strong></td>
                        <td><strong>30,000</strong></td>
                    </tr>
                </tbody>
            </table>

            <h4>Channel Strategy (Year 1)</h4>
            <table>
                <thead>
                    <tr>
                        <th>Channel</th>
                        <th>Activity</th>
                        <th>Tests Generated</th>
                        <th>Cost</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Direct Founder Sales</strong></td>
                        <td>CEO/CSO personally visits top 30 practices</td>
                        <td>12,000</td>
                        <td>Time cost only</td>
                    </tr>
                    <tr>
                        <td><strong>Clinical Specialists (2 FTE)</strong></td>
                        <td>Dedicated reps covering FL, NY/NJ, TX</td>
                        <td>10,000</td>
                        <td>$300K comp</td>
                    </tr>
                    <tr>
                        <td><strong>Conference Marketing</strong></td>
                        <td>ARVO, AAO, Retina Society presentations</td>
                        <td>3,000 (indirect)</td>
                        <td>$75K</td>
                    </tr>
                    <tr>
                        <td><strong>Digital/Inbound</strong></td>
                        <td>Medical website, physician education portal</td>
                        <td>2,000</td>
                        <td>$50K</td>
                    </tr>
                    <tr>
                        <td><strong>KOL Referral Network</strong></td>
                        <td>Advisory board members referring colleagues</td>
                        <td>3,000</td>
                        <td>$25K (honoraria)</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total</strong></td>
                        <td></td>
                        <td><strong>30,000</strong></td>
                        <td><strong>$450K</strong></td>
                    </tr>
                </tbody>
            </table>

            <div class="warning-box">
                <h4>Why Founder-Led Sales Matters</h4>
                <p>In diagnostic company early stages, the founder is the most effective sales person. Not because they are trained in sales, but because physicians evaluating a novel diagnostic want to speak to the scientist who developed it.</p>
                <p style="margin-top: 10px;">Exact Sciences' Kevin Conroy personally visited oncologists during Cologuard's early launch. Foundation Medicine's founders presented directly to cancer centers. This pattern repeats across successful diagnostic launches.</p>
            </div>

            <h3>Year 2 (2028): Coverage-Fueled Expansion â€” 149,000 Tests</h3>

            <div class="highlight-box">
                <h4>Strategic Phase: "Scale with Coverage"</h4>
                <p>Year 2 is the inflection point. MolDX coverage (expected Q3-Q4 2027) transforms the selling proposition from "novel test your patients pay $250 for" to "covered test you can order like any other lab."</p>
            </div>

            <h4>Target Physician Segments</h4>
            <table>
                <thead>
                    <tr>
                        <th>Segment</th>
                        <th># Practices</th>
                        <th># Physicians</th>
                        <th>Tests/Physician/Year</th>
                        <th>Total Tests</th>
                        <th>Change vs Y1</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Academic Retina Centers</td>
                        <td>30</td>
                        <td>120</td>
                        <td>150</td>
                        <td>18,000</td>
                        <td>+150%</td>
                    </tr>
                    <tr>
                        <td>Large Retina Practices</td>
                        <td>80</td>
                        <td>400</td>
                        <td>100</td>
                        <td>40,000</td>
                        <td>+300%</td>
                    </tr>
                    <tr>
                        <td>Ophthalmology Groups</td>
                        <td>120</td>
                        <td>480</td>
                        <td>65</td>
                        <td>31,200</td>
                        <td>+593%</td>
                    </tr>
                    <tr>
                        <td>Primary Care Networks</td>
                        <td>40</td>
                        <td>800</td>
                        <td>45</td>
                        <td>36,000</td>
                        <td>+586%</td>
                    </tr>
                    <tr>
                        <td>Community Ophthalmology</td>
                        <td>100</td>
                        <td>200</td>
                        <td>40</td>
                        <td>8,000</td>
                        <td>New segment</td>
                    </tr>
                    <tr>
                        <td>Concierge/Executive Health</td>
                        <td>40</td>
                        <td>120</td>
                        <td>80</td>
                        <td>9,600</td>
                        <td>+205%</td>
                    </tr>
                    <tr>
                        <td>Optometry Referral Partners</td>
                        <td>50</td>
                        <td>200</td>
                        <td>35</td>
                        <td>7,000</td>
                        <td>New segment</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total</strong></td>
                        <td><strong>460</strong></td>
                        <td><strong>2,320</strong></td>
                        <td><strong>64 avg</strong></td>
                        <td><strong>149,800</strong></td>
                        <td><strong>+399%</strong></td>
                    </tr>
                </tbody>
            </table>

            <h4>Geographic Expansion</h4>
            <table>
                <thead>
                    <tr>
                        <th>Phase</th>
                        <th>States Added</th>
                        <th>Why</th>
                        <th>New Practices</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Existing (Year 1)</td>
                        <td>CA, FL, NY/NJ, TX, MA</td>
                        <td>Deepen penetration</td>
                        <td>+50 practices</td>
                    </tr>
                    <tr>
                        <td>Wave 2 (Q1-Q2 2028)</td>
                        <td>PA, IL, OH, AZ</td>
                        <td>High AMD prevalence; major academic centers</td>
                        <td>+100 practices</td>
                    </tr>
                    <tr>
                        <td>Wave 3 (Q3-Q4 2028)</td>
                        <td>NC, MI, GA, WA, MN, CO</td>
                        <td>Regional expansion; academic partnerships</td>
                        <td>+120 practices</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total Year 2</strong></td>
                        <td><strong>17 states</strong></td>
                        <td>65% of US 55+ population</td>
                        <td><strong>460 practices</strong></td>
                    </tr>
                </tbody>
            </table>

            <h3>Year 3 (2029): Mainstream Adoption â€” 448,000 Tests</h3>

            <div class="highlight-box">
                <h4>Strategic Phase: "Standard of Care Pursuit"</h4>
                <p>Year 3 is about transitioning from "innovative new test" to "standard practice." The goal is to make AMD risk assessment via blood test as routine as cholesterol screening.</p>
            </div>

            <table>
                <thead>
                    <tr>
                        <th>Segment</th>
                        <th># Practices</th>
                        <th># Physicians</th>
                        <th>Tests/Physician/Year</th>
                        <th>Total Tests</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Retina Centers (Academic + Private)</td>
                        <td>200</td>
                        <td>800</td>
                        <td>140</td>
                        <td>112,000</td>
                    </tr>
                    <tr>
                        <td>Ophthalmology Groups</td>
                        <td>400</td>
                        <td>1,600</td>
                        <td>75</td>
                        <td>120,000</td>
                    </tr>
                    <tr>
                        <td>Primary Care Networks</td>
                        <td>150</td>
                        <td>3,000</td>
                        <td>45</td>
                        <td>135,000</td>
                    </tr>
                    <tr>
                        <td>Community Ophthalmology</td>
                        <td>250</td>
                        <td>500</td>
                        <td>50</td>
                        <td>25,000</td>
                    </tr>
                    <tr>
                        <td>Optometry Referral Partners</td>
                        <td>200</td>
                        <td>800</td>
                        <td>40</td>
                        <td>32,000</td>
                    </tr>
                    <tr>
                        <td>Concierge/Executive Health</td>
                        <td>80</td>
                        <td>240</td>
                        <td>100</td>
                        <td>24,000</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total</strong></td>
                        <td><strong>1,280</strong></td>
                        <td><strong>6,940</strong></td>
                        <td><strong>65 avg</strong></td>
                        <td><strong>448,000</strong></td>
                    </tr>
                </tbody>
            </table>

            <p style="margin-top: 20px;"><strong>Geographic Coverage:</strong> 35 states (90% of US 55+ population)</p>

            <p style="margin-top: 15px;"><strong>Key Year 3 Initiatives:</strong></p>
            <ul>
                <li>Pursue clinical guideline inclusion (AAO, ACP)</li>
                <li>National EHR integration (Epic, Cerner/Oracle Health)</li>
                <li>Launch optometry referral program</li>
                <li>Begin direct-to-consumer awareness campaign</li>
            </ul>

            <h3>Year 4 (2030): Market Penetration â€” 940,000 Tests</h3>

            <div class="highlight-box">
                <h4>Strategic Phase: "Scalable Infrastructure"</h4>
            </div>

            <table>
                <thead>
                    <tr>
                        <th>Segment</th>
                        <th># Physicians</th>
                        <th>Tests/Physician/Year</th>
                        <th>Total Tests</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Retina Specialists</td>
                        <td>1,200</td>
                        <td>150</td>
                        <td>180,000</td>
                    </tr>
                    <tr>
                        <td>General Ophthalmology</td>
                        <td>3,500</td>
                        <td>80</td>
                        <td>280,000</td>
                    </tr>
                    <tr>
                        <td>Primary Care</td>
                        <td>6,000</td>
                        <td>50</td>
                        <td>300,000</td>
                    </tr>
                    <tr>
                        <td>Optometry (referral)</td>
                        <td>2,000</td>
                        <td>45</td>
                        <td>90,000</td>
                    </tr>
                    <tr>
                        <td>Concierge/Executive Health</td>
                        <td>500</td>
                        <td>120</td>
                        <td>60,000</td>
                    </tr>
                    <tr>
                        <td>Direct-to-Consumer</td>
                        <td>N/A</td>
                        <td>N/A</td>
                        <td>30,000</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total</strong></td>
                        <td><strong>13,200</strong></td>
                        <td><strong>71 avg</strong></td>
                        <td><strong>940,000</strong></td>
                    </tr>
                </tbody>
            </table>

            <p style="margin-top: 20px;"><strong>Geographic Coverage:</strong> 48 states (national)</p>

            <h3>Year 5 (2031): Market Leadership â€” 1,520,000 Tests</h3>

            <div class="highlight-box">
                <h4>Strategic Phase: "Category Leader"</h4>
            </div>

            <table>
                <thead>
                    <tr>
                        <th>Segment</th>
                        <th># Physicians</th>
                        <th>Tests/Physician/Year</th>
                        <th>Total Tests</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Retina Specialists</td>
                        <td>1,500</td>
                        <td>160</td>
                        <td>240,000</td>
                    </tr>
                    <tr>
                        <td>General Ophthalmology</td>
                        <td>5,000</td>
                        <td>90</td>
                        <td>450,000</td>
                    </tr>
                    <tr>
                        <td>Primary Care</td>
                        <td>10,000</td>
                        <td>55</td>
                        <td>550,000</td>
                    </tr>
                    <tr>
                        <td>Optometry (referral)</td>
                        <td>3,500</td>
                        <td>50</td>
                        <td>175,000</td>
                    </tr>
                    <tr>
                        <td>Concierge/Executive Health</td>
                        <td>700</td>
                        <td>130</td>
                        <td>91,000</td>
                    </tr>
                    <tr>
                        <td>Direct-to-Consumer</td>
                        <td>N/A</td>
                        <td>N/A</td>
                        <td>14,000</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total</strong></td>
                        <td><strong>20,700</strong></td>
                        <td><strong>73 avg</strong></td>
                        <td><strong>1,520,000</strong></td>
                    </tr>
                </tbody>
            </table>

            <p style="margin-top: 20px;"><strong>Geographic Coverage:</strong> 50 states + territories</p>
        </div>

        <!-- Section 2: Physician Adoption Model -->
        <div class="section">
            <h2>2. Physician Adoption Model: The Math</h2>

            <h3>Total Addressable Physician Universe</h3>
            <table>
                <thead>
                    <tr>
                        <th>Segment</th>
                        <th>Total US Physicians</th>
                        <th>Relevance to AMD Testing</th>
                        <th>Accessible Year 1</th>
                        <th>Year 5 Target</th>
                        <th>Year 5 Penetration</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Retina Specialists</td>
                        <td>2,500</td>
                        <td>Highest (see AMD daily)</td>
                        <td>185</td>
                        <td>1,500</td>
                        <td><strong>60%</strong></td>
                    </tr>
                    <tr>
                        <td>General Ophthalmologists</td>
                        <td>16,000</td>
                        <td>High (manage AMD patients)</td>
                        <td>210</td>
                        <td>5,000</td>
                        <td><strong>31%</strong></td>
                    </tr>
                    <tr>
                        <td>Primary Care Physicians</td>
                        <td>210,000</td>
                        <td>Medium (preventive care)</td>
                        <td>150</td>
                        <td>10,000</td>
                        <td><strong>5%</strong></td>
                    </tr>
                    <tr>
                        <td>Optometrists</td>
                        <td>38,000</td>
                        <td>Medium (refer AMD suspects)</td>
                        <td>0</td>
                        <td>3,500</td>
                        <td><strong>9%</strong></td>
                    </tr>
                    <tr>
                        <td>Other (concierge, etc.)</td>
                        <td>15,000</td>
                        <td>Low-Medium</td>
                        <td>45</td>
                        <td>700</td>
                        <td><strong>5%</strong></td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total</strong></td>
                        <td><strong>281,500</strong></td>
                        <td></td>
                        <td><strong>590</strong></td>
                        <td><strong>20,700</strong></td>
                        <td><strong>7.4%</strong></td>
                    </tr>
                </tbody>
            </table>

            <h3>Physician Adoption Curve</h3>
            <table>
                <thead>
                    <tr>
                        <th>Year</th>
                        <th>Ordering Physicians</th>
                        <th>% of Target Universe</th>
                        <th>Avg Tests/Physician</th>
                        <th>Total Tests</th>
                        <th>Adoption Phase</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Year 1</td>
                        <td>470</td>
                        <td>0.17%</td>
                        <td>64</td>
                        <td>30,000</td>
                        <td>Innovators</td>
                    </tr>
                    <tr>
                        <td>Year 2</td>
                        <td>2,320</td>
                        <td>0.82%</td>
                        <td>64</td>
                        <td>149,000</td>
                        <td>Early Adopters</td>
                    </tr>
                    <tr>
                        <td>Year 3</td>
                        <td>6,940</td>
                        <td>2.5%</td>
                        <td>65</td>
                        <td>448,000</td>
                        <td>Early Majority (Start)</td>
                    </tr>
                    <tr>
                        <td>Year 4</td>
                        <td>13,200</td>
                        <td>4.7%</td>
                        <td>71</td>
                        <td>940,000</td>
                        <td>Early Majority</td>
                    </tr>
                    <tr>
                        <td>Year 5</td>
                        <td>20,700</td>
                        <td>7.4%</td>
                        <td>73</td>
                        <td>1,520,000</td>
                        <td>Early Majority (Peak)</td>
                    </tr>
                </tbody>
            </table>

            <div class="success-box">
                <h4>Why 7.4% Physician Penetration in Year 5 Is Conservative</h4>
                <p>For context, comparable diagnostic tests at maturity:</p>
                <ul>
                    <li><strong>Oncotype DX:</strong> ordered by approximately 80% of eligible oncologists</li>
                    <li><strong>Cologuard:</strong> ordered by approximately 35% of primary care physicians</li>
                    <li><strong>Foundation Medicine:</strong> ordered by approximately 60% of oncologists</li>
                </ul>
                <p style="margin-top: 15px;">A1 Diagnosis at 7.4% overall penetration (60% of retina specialists, 31% of ophthalmologists, 5% of primary care) is well below mature diagnostic adoption rates. This leaves substantial upside beyond Year 5.</p>
            </div>

            <h3>Tests Per Physician: Reasonableness Check</h3>
            <p><strong>Is 64-73 tests per physician per year realistic?</strong></p>

            <table>
                <thead>
                    <tr>
                        <th>Benchmark</th>
                        <th>Tests/Physician/Year</th>
                        <th>Context</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Cholesterol screening</td>
                        <td>300-500</td>
                        <td>Routine preventive care</td>
                    </tr>
                    <tr>
                        <td>PSA screening</td>
                        <td>150-250</td>
                        <td>Targeted preventive care</td>
                    </tr>
                    <tr>
                        <td>Cologuard orders</td>
                        <td>100-200</td>
                        <td>Screening-age patients</td>
                    </tr>
                    <tr>
                        <td>Oncotype DX</td>
                        <td>30-60</td>
                        <td>Narrow indication</td>
                    </tr>
                    <tr style="background-color: #dbeafe;">
                        <td><strong>A1 Diagnosis target</strong></td>
                        <td><strong>64-73</strong></td>
                        <td><strong>Risk assessment for 55+ patients</strong></td>
                    </tr>
                </tbody>
            </table>

            <p style="margin-top: 20px;">At 64 tests per physician per year, that is approximately <strong>1.2 tests per week</strong>. For a retina specialist seeing 30-40 patients per day, ordering 1-2 blood-based AMD risk tests per week is modest. For a primary care physician, 45 tests per year is less than 1 per week.</p>

            <div class="warning-box">
                <h4>Conservative Assumption</h4>
                <p>If AMD blood testing becomes part of routine preventive care (like cholesterol), per-physician volumes could be <strong>5-10x higher</strong> than our projections.</p>
            </div>
        </div>

        <!-- Section 3: Sales & Marketing Infrastructure -->
        <div class="section">
            <h2>3. Sales & Marketing Infrastructure Build</h2>

            <h3>Team Scaling Plan</h3>

            <h4>Year 1 (2027): Lean Founding Team â€” $715K Total Compensation</h4>
            <table>
                <thead>
                    <tr>
                        <th>Role</th>
                        <th>Headcount</th>
                        <th>Hire Date</th>
                        <th>OTE</th>
                        <th>Purpose</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>VP Commercial Operations</td>
                        <td>1</td>
                        <td>Month -3 (Q4 2026)</td>
                        <td>$220K</td>
                        <td>Build commercial infrastructure; lead all sales/marketing</td>
                    </tr>
                    <tr>
                        <td>Clinical Account Specialist (FL + Southeast)</td>
                        <td>1</td>
                        <td>Month 1 (Q1 2027)</td>
                        <td>$130K</td>
                        <td>Cover Florida + Southeast academic centers</td>
                    </tr>
                    <tr>
                        <td>Clinical Account Specialist (Northeast)</td>
                        <td>1</td>
                        <td>Month 3 (Q2 2027)</td>
                        <td>$130K</td>
                        <td>Cover NY/NJ/PA/MA academic centers</td>
                    </tr>
                    <tr>
                        <td>Marketing Manager</td>
                        <td>1</td>
                        <td>Month 1 (Q1 2027)</td>
                        <td>$95K</td>
                        <td>Digital marketing, physician education, conference materials</td>
                    </tr>
                    <tr>
                        <td>Reimbursement Director</td>
                        <td>1</td>
                        <td>Month -3 (Q4 2026)</td>
                        <td>$140K</td>
                        <td>MolDX strategy, payer engagement, LCD submissions</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total Year 1</strong></td>
                        <td><strong>5</strong></td>
                        <td></td>
                        <td><strong>$715K</strong></td>
                        <td></td>
                    </tr>
                </tbody>
            </table>

            <div class="highlight-box">
                <h4>Note on Founder Sales</h4>
                <p>CEO and CSO cover California + Texas personally in Year 1. This is not reflected in headcount cost but is the primary sales engine for Year 1. The Clinical Account Specialists extend reach to Florida and Northeast.</p>
            </div>

            <h4>Year 2 (2028): Commercial Expansion â€” $1.82M Total Compensation</h4>
            <table>
                <thead>
                    <tr>
                        <th>Role</th>
                        <th>Headcount</th>
                        <th>Hire Date</th>
                        <th>Comp (OTE)</th>
                        <th>Purpose</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>VP Commercial Operations</td>
                        <td>1</td>
                        <td>Existing</td>
                        <td>$240K</td>
                        <td>Promoted; expanded scope</td>
                    </tr>
                    <tr>
                        <td>Territory Account Managers</td>
                        <td>5</td>
                        <td>Q1-Q2 2028</td>
                        <td>$650K</td>
                        <td>Geographic territories: CA, FL, Northeast, Midwest, TX/South</td>
                    </tr>
                    <tr>
                        <td>Clinical Educators</td>
                        <td>2</td>
                        <td>Q1 2028</td>
                        <td>$240K</td>
                        <td>Grand rounds, physician education, clinical support</td>
                    </tr>
                    <tr>
                        <td>Payer Relations Manager</td>
                        <td>1</td>
                        <td>Q1 2028</td>
                        <td>$130K</td>
                        <td>Commercial payer negotiations, coverage expansion</td>
                    </tr>
                    <tr>
                        <td>Marketing Team Lead</td>
                        <td>1</td>
                        <td>Q1 2028</td>
                        <td>$120K</td>
                        <td>Upgrade from marketing manager</td>
                    </tr>
                    <tr>
                        <td>Digital Marketing Specialist</td>
                        <td>1</td>
                        <td>Q2 2028</td>
                        <td>$85K</td>
                        <td>Physician digital engagement, SEO, content</td>
                    </tr>
                    <tr>
                        <td>Sales Operations Analyst</td>
                        <td>1</td>
                        <td>Q2 2028</td>
                        <td>$80K</td>
                        <td>CRM management, sales analytics, territory optimization</td>
                    </tr>
                    <tr>
                        <td>Reimbursement Director</td>
                        <td>1</td>
                        <td>Existing</td>
                        <td>$150K</td>
                        <td>Continued payer strategy</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total Year 2</strong></td>
                        <td><strong>13</strong></td>
                        <td></td>
                        <td><strong>$1.82M</strong></td>
                        <td></td>
                    </tr>
                </tbody>
            </table>

            <h4>Territory Manager Productivity Model</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Year 2 Target</th>
                        <th>Benchmark</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Practices per territory manager</td>
                        <td>60-80</td>
                        <td>Industry standard: 50-100</td>
                    </tr>
                    <tr>
                        <td>Active ordering physicians per TM</td>
                        <td>350-400</td>
                        <td>â€”</td>
                    </tr>
                    <tr>
                        <td>Tests per TM territory</td>
                        <td>25,000-30,000</td>
                        <td>â€”</td>
                    </tr>
                    <tr>
                        <td>Revenue per TM</td>
                        <td>$6-7.5M</td>
                        <td>Oncotype DX TMs generate $5-10M</td>
                    </tr>
                    <tr>
                        <td>Cost of TM (fully loaded)</td>
                        <td>$160K</td>
                        <td>Including benefits + travel</td>
                    </tr>
                    <tr style="background-color: #d1fae5; font-weight: 700;">
                        <td><strong>ROI per Territory Manager</strong></td>
                        <td><strong>37-47x</strong></td>
                        <td></td>
                    </tr>
                </tbody>
            </table>

            <h4>Year 3-5 Scaling Summary</h4>
            <table>
                <thead>
                    <tr>
                        <th>Year</th>
                        <th>Total Commercial Headcount</th>
                        <th>Total Comp</th>
                        <th>Revenue/Employee</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Year 1</td>
                        <td>5</td>
                        <td>$715K</td>
                        <td>$1.5M</td>
                    </tr>
                    <tr>
                        <td>Year 2</td>
                        <td>13</td>
                        <td>$1.82M</td>
                        <td>$11.5M</td>
                    </tr>
                    <tr>
                        <td>Year 3</td>
                        <td>33</td>
                        <td>$4.43M</td>
                        <td>$3.4M</td>
                    </tr>
                    <tr>
                        <td>Year 4</td>
                        <td>55</td>
                        <td>$7.5M</td>
                        <td>$4.3M</td>
                    </tr>
                    <tr>
                        <td>Year 5</td>
                        <td>80</td>
                        <td>$11.0M</td>
                        <td>$4.8M</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <!-- Section 4: Reimbursement Strategy Timeline -->
        <div class="section">
            <h2>4. Reimbursement Strategy Timeline</h2>

            <h3>Pre-Launch Phase (Q3-Q4 2026): Building the Foundation</h3>
            <table>
                <thead>
                    <tr>
                        <th>Month</th>
                        <th>Activity</th>
                        <th>Deliverable</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Jul 2026</strong></td>
                        <td>Engage reimbursement strategy consultant</td>
                        <td>Signed engagement letter</td>
                    </tr>
                    <tr>
                        <td><strong>Aug 2026</strong></td>
                        <td>Begin PLA code application to AMA</td>
                        <td>PLA application submitted</td>
                    </tr>
                    <tr>
                        <td><strong>Sep 2026</strong></td>
                        <td>MolDX pre-submission meeting with Palmetto GBA</td>
                        <td>Feedback on submission requirements</td>
                    </tr>
                    <tr>
                        <td><strong>Oct 2026</strong></td>
                        <td>Prepare Technical Assessment dossier</td>
                        <td>Draft TA package</td>
                    </tr>
                    <tr>
                        <td><strong>Nov 2026</strong></td>
                        <td>Finalize TA dossier; identify priority MAC jurisdictions</td>
                        <td>Final TA package; MAC strategy</td>
                    </tr>
                    <tr>
                        <td><strong>Dec 2026</strong></td>
                        <td>Pre-engagement with top 3 commercial payers</td>
                        <td>Initial medical director meetings</td>
                    </tr>
                </tbody>
            </table>

            <h3>Year 1 Post-Launch (Q1-Q4 2027): Securing Coverage</h3>
            <table>
                <thead>
                    <tr>
                        <th>Month</th>
                        <th>Activity</th>
                        <th>Coverage Status</th>
                        <th>Volume Impact</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Jan 2027</strong></td>
                        <td>CLIA launch; submit MolDX TA Day 1</td>
                        <td>No coverage; 100% self-pay</td>
                        <td>800 tests</td>
                    </tr>
                    <tr>
                        <td><strong>Feb 2027</strong></td>
                        <td>Submit LCD request to Palmetto & Noridian</td>
                        <td>Pending</td>
                        <td>1,200 tests</td>
                    </tr>
                    <tr>
                        <td><strong>Mar 2027</strong></td>
                        <td>MolDX acknowledges receipt; begins review</td>
                        <td>Pending</td>
                        <td>1,500 tests</td>
                    </tr>
                    <tr>
                        <td><strong>Apr 2027</strong></td>
                        <td>Present early clinical data at ARVO</td>
                        <td>Pending</td>
                        <td>2,000 tests</td>
                    </tr>
                    <tr>
                        <td><strong>May 2027</strong></td>
                        <td>First peer-reviewed publication submitted</td>
                        <td>Pending</td>
                        <td>2,200 tests</td>
                    </tr>
                    <tr>
                        <td><strong>Jun 2027</strong></td>
                        <td>MolDX technical review ongoing</td>
                        <td>Pending</td>
                        <td>2,500 tests</td>
                    </tr>
                    <tr style="background-color: #d1fae5;">
                        <td><strong>Jul 2027</strong></td>
                        <td>MolDX coverage decision â€” TARGET: COVERAGE ACHIEVED</td>
                        <td><strong>MolDX LIVE</strong></td>
                        <td><strong>3,500 tests (jump)</strong></td>
                    </tr>
                    <tr>
                        <td><strong>Aug 2027</strong></td>
                        <td>Coverage announcement drives physician pull-through</td>
                        <td>MolDX covered</td>
                        <td>4,000 tests</td>
                    </tr>
                    <tr>
                        <td><strong>Sep 2027</strong></td>
                        <td>LCD draft published for public comment</td>
                        <td>MolDX + LCD pending</td>
                        <td>4,200 tests</td>
                    </tr>
                    <tr>
                        <td><strong>Oct 2027</strong></td>
                        <td>LCD public comment period; AAO presentation</td>
                        <td>MolDX + LCD pending</td>
                        <td>4,500 tests</td>
                    </tr>
                    <tr style="background-color: #d1fae5;">
                        <td><strong>Nov 2027</strong></td>
                        <td>LCD finalized; commercial payer decisions begin</td>
                        <td><strong>MolDX + LCD live</strong></td>
                        <td><strong>5,000 tests (jump)</strong></td>
                    </tr>
                    <tr>
                        <td><strong>Dec 2027</strong></td>
                        <td>First major commercial payer coverage announced</td>
                        <td>MolDX + LCD + 1 commercial</td>
                        <td>5,500 tests</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Year 1 Total</strong></td>
                        <td></td>
                        <td></td>
                        <td><strong>~37,000 tests</strong></td>
                    </tr>
                </tbody>
            </table>

            <div class="success-box">
                <h4>Coverage-Driven Volume Acceleration</h4>
                <p>The monthly ramp shows how MolDX coverage (Month 7) and LCD coverage (Month 11) create step-function increases in monthly volume. This is the mechanism behind the accelerated case projections.</p>
            </div>

            <h3>Year 2 (2028): Coverage Cascade</h3>
            <table>
                <thead>
                    <tr>
                        <th>Quarter</th>
                        <th>Coverage Milestone</th>
                        <th>Cumulative Coverage</th>
                        <th>Quarterly Tests</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Q1 2028</strong></td>
                        <td>LCD expansion to 2 additional MACs; UHC coverage</td>
                        <td>MolDX + 3 LCDs + UHC</td>
                        <td>25,000</td>
                    </tr>
                    <tr>
                        <td><strong>Q2 2028</strong></td>
                        <td>Anthem/Elevance, Aetna coverage; 2 more LCDs</td>
                        <td>5 LCDs + 3 major commercial</td>
                        <td>35,000</td>
                    </tr>
                    <tr>
                        <td><strong>Q3 2028</strong></td>
                        <td>Cigna, Humana coverage; NCD process initiated</td>
                        <td>5 LCDs + 5 major commercial</td>
                        <td>42,000</td>
                    </tr>
                    <tr>
                        <td><strong>Q4 2028</strong></td>
                        <td>Near-national coverage; remaining commercial payers</td>
                        <td>7 LCDs + all major commercial</td>
                        <td>47,000</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Year 2 Total</strong></td>
                        <td></td>
                        <td>~70% of lives covered</td>
                        <td><strong>149,000</strong></td>
                    </tr>
                </tbody>
            </table>

            <h3>Key Payer Engagement Milestones</h3>
            <table>
                <thead>
                    <tr>
                        <th>Payer</th>
                        <th>Covered Lives</th>
                        <th>Target Coverage Date</th>
                        <th>Strategy</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Medicare (MolDX)</strong></td>
                        <td>65M+</td>
                        <td>Q3 2027 (Month 6-9)</td>
                        <td>Technical Assessment + clinical utility data</td>
                    </tr>
                    <tr>
                        <td><strong>Medicare (LCD â€” Palmetto)</strong></td>
                        <td>12M</td>
                        <td>Q4 2027 (Month 9-12)</td>
                        <td>LCD application + public comment</td>
                    </tr>
                    <tr>
                        <td><strong>Medicare (LCD â€” Noridian)</strong></td>
                        <td>15M</td>
                        <td>Q4 2027 (Month 9-12)</td>
                        <td>Parallel LCD application</td>
                    </tr>
                    <tr>
                        <td><strong>UnitedHealthcare</strong></td>
                        <td>51M</td>
                        <td>Q1 2028</td>
                        <td>Medical policy review; leverage Medicare decision</td>
                    </tr>
                    <tr>
                        <td><strong>Anthem/Elevance</strong></td>
                        <td>47M</td>
                        <td>Q2 2028</td>
                        <td>Lab management program submission</td>
                    </tr>
                    <tr>
                        <td><strong>Aetna/CVS Health</strong></td>
                        <td>23M</td>
                        <td>Q2 2028</td>
                        <td>Clinical policy bulletin</td>
                    </tr>
                    <tr>
                        <td><strong>Cigna</strong></td>
                        <td>17M</td>
                        <td>Q3 2028</td>
                        <td>Coverage policy review</td>
                    </tr>
                    <tr>
                        <td><strong>Humana</strong></td>
                        <td>17M</td>
                        <td>Q3 2028</td>
                        <td>Medical coverage policy</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <!-- Section 5: Operational Scaling -->
        <div class="section">
            <h2>5. Operational Scaling Plan</h2>

            <h3>Lab Capacity Model</h3>

            <div class="highlight-box">
                <h4>Core Constraint: LC-MS/MS Throughput</h4>
                <p>The LC-MS/MS instrument is the rate-limiting factor for test volume. Each instrument has maximum daily throughput depending on run time per sample and operating hours.</p>
                <ul style="margin-top: 10px;">
                    <li>Run time per sample: 15-20 minutes</li>
                    <li>Samples per batch: 10-12</li>
                    <li>Batches per instrument per day (single shift): 4-5</li>
                    <li><strong>Tests per instrument per day (single shift): 40-60</strong></li>
                    <li><strong>Tests per instrument per day (double shift): 80-120</strong></li>
                </ul>
            </div>

            <h3>Capacity Planning by Year</h3>
            <table>
                <thead>
                    <tr>
                        <th>Year</th>
                        <th>Annual Tests</th>
                        <th>Tests/Day Required</th>
                        <th>Instruments Needed</th>
                        <th>Shifts</th>
                        <th>Lab Staff</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Year 1</td>
                        <td>30,000</td>
                        <td>120</td>
                        <td>1</td>
                        <td>Double</td>
                        <td>1 Lab Director + 3 CLS Techs</td>
                    </tr>
                    <tr>
                        <td>Year 2</td>
                        <td>149,000</td>
                        <td>596</td>
                        <td>2 (+1 new)</td>
                        <td>Double</td>
                        <td>1 Lab Director + 2 Supervisors + 8 CLS Techs</td>
                    </tr>
                    <tr>
                        <td>Year 3</td>
                        <td>448,000</td>
                        <td>1,792</td>
                        <td>5 (+3 new)</td>
                        <td>Double + weekend</td>
                        <td>1 Lab Director + 4 Supervisors + 18 CLS Techs</td>
                    </tr>
                    <tr>
                        <td>Year 4</td>
                        <td>940,000</td>
                        <td>3,760</td>
                        <td>10 (+5 new)</td>
                        <td>Triple</td>
                        <td>2 Lab Directors + 8 Supervisors + 35 CLS Techs</td>
                    </tr>
                    <tr>
                        <td>Year 5</td>
                        <td>1,520,000</td>
                        <td>6,080</td>
                        <td>16 (+6 new)</td>
                        <td>Triple</td>
                        <td>2 Lab Directors + 12 Supervisors + 55 CLS Techs</td>
                    </tr>
                </tbody>
            </table>

            <h3>Lab Staffing Detail</h3>
            <table>
                <thead>
                    <tr>
                        <th>Role</th>
                        <th>Year 1</th>
                        <th>Year 2</th>
                        <th>Year 3</th>
                        <th>Year 4</th>
                        <th>Year 5</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Lab Director (CLIA required)</td>
                        <td>1</td>
                        <td>1</td>
                        <td>1</td>
                        <td>2</td>
                        <td>2</td>
                    </tr>
                    <tr>
                        <td>Lab Supervisor</td>
                        <td>0</td>
                        <td>2</td>
                        <td>4</td>
                        <td>8</td>
                        <td>12</td>
                    </tr>
                    <tr>
                        <td>Clinical Lab Scientists (CLS)</td>
                        <td>3</td>
                        <td>8</td>
                        <td>18</td>
                        <td>35</td>
                        <td>55</td>
                    </tr>
                    <tr>
                        <td>Sample Processing Techs</td>
                        <td>1</td>
                        <td>3</td>
                        <td>8</td>
                        <td>15</td>
                        <td>25</td>
                    </tr>
                    <tr>
                        <td>Quality Assurance</td>
                        <td>1</td>
                        <td>1</td>
                        <td>2</td>
                        <td>3</td>
                        <td>4</td>
                    </tr>
                    <tr>
                        <td>IT/LIMS</td>
                        <td>0</td>
                        <td>1</td>
                        <td>2</td>
                        <td>3</td>
                        <td>4</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total Lab Staff</strong></td>
                        <td><strong>6</strong></td>
                        <td><strong>16</strong></td>
                        <td><strong>35</strong></td>
                        <td><strong>66</strong></td>
                        <td><strong>102</strong></td>
                    </tr>
                </tbody>
            </table>

            <h3>Facility Planning</h3>
            <table>
                <thead>
                    <tr>
                        <th>Year</th>
                        <th>Lab Space Needed</th>
                        <th>Facility Type</th>
                        <th>Est. Lease Cost</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Year 1</td>
                        <td>2,000-3,000 sq ft</td>
                        <td>Single lab suite</td>
                        <td>$72K/year</td>
                    </tr>
                    <tr>
                        <td>Year 2</td>
                        <td>5,000-7,000 sq ft</td>
                        <td>Expanded suite or second space</td>
                        <td>$180K/year</td>
                    </tr>
                    <tr>
                        <td>Year 3</td>
                        <td>12,000-15,000 sq ft</td>
                        <td>Dedicated lab facility</td>
                        <td>$450K/year</td>
                    </tr>
                    <tr>
                        <td>Year 4</td>
                        <td>25,000-30,000 sq ft</td>
                        <td>Large-scale lab facility</td>
                        <td>$900K/year</td>
                    </tr>
                    <tr>
                        <td>Year 5</td>
                        <td>40,000-50,000 sq ft</td>
                        <td>Enterprise lab facility or multiple sites</td>
                        <td>$1.5M/year</td>
                    </tr>
                </tbody>
            </table>

            <h3>Sample Logistics Plan</h3>
            <table>
                <thead>
                    <tr>
                        <th>Year</th>
                        <th>Daily Sample Volume</th>
                        <th>Collection Method</th>
                        <th>Turnaround Time</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Year 1</td>
                        <td>120</td>
                        <td>Blood draw kits shipped to practices; samples returned via overnight courier</td>
                        <td>7-10 business days</td>
                    </tr>
                    <tr>
                        <td>Year 2</td>
                        <td>600</td>
                        <td>Same + regional phlebotomy partnerships (Quest PSC, LabCorp PSC)</td>
                        <td>5-7 business days</td>
                    </tr>
                    <tr>
                        <td>Year 3</td>
                        <td>1,800</td>
                        <td>National phlebotomy network + major reference lab collection partnerships</td>
                        <td>5-7 business days</td>
                    </tr>
                    <tr>
                        <td>Year 4</td>
                        <td>3,800</td>
                        <td>Integrated collection hub model (5-8 regional hubs)</td>
                        <td>3-5 business days</td>
                    </tr>
                    <tr>
                        <td>Year 5</td>
                        <td>6,100</td>
                        <td>Full national collection network</td>
                        <td>3-5 business days</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <!-- Section 6: Key Milestones & Success Metrics -->
        <div class="section">
            <h2>6. Key Milestones & Success Metrics</h2>

            <h3>Year 1 Quarterly Milestones</h3>
            <table>
                <thead>
                    <tr>
                        <th>Quarter</th>
                        <th>Tests</th>
                        <th>Physicians</th>
                        <th>Coverage</th>
                        <th>Revenue</th>
                        <th>Key Milestone</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Q1 2027</strong></td>
                        <td>3,500</td>
                        <td>80</td>
                        <td>MolDX submitted</td>
                        <td>$875K</td>
                        <td>CLIA launch; first test processed</td>
                    </tr>
                    <tr>
                        <td><strong>Q2 2027</strong></td>
                        <td>5,700</td>
                        <td>170</td>
                        <td>MolDX under review</td>
                        <td>$1.43M</td>
                        <td>100th ordering physician; ARVO presentation</td>
                    </tr>
                    <tr style="background-color: #d1fae5;">
                        <td><strong>Q3 2027</strong></td>
                        <td>9,200</td>
                        <td>300</td>
                        <td><strong>MolDX coverage live</strong></td>
                        <td>$2.3M</td>
                        <td><strong>Medicare coverage achieved</strong></td>
                    </tr>
                    <tr style="background-color: #d1fae5;">
                        <td><strong>Q4 2027</strong></td>
                        <td>11,600</td>
                        <td>470</td>
                        <td><strong>MolDX + LCD live</strong></td>
                        <td>$2.9M</td>
                        <td><strong>First LCD; 10,000th test milestone</strong></td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Year 1 Total</strong></td>
                        <td><strong>30,000</strong></td>
                        <td><strong>470</strong></td>
                        <td></td>
                        <td><strong>$7.5M</strong></td>
                        <td></td>
                    </tr>
                </tbody>
            </table>

            <h3>Year 2 Quarterly Milestones</h3>
            <table>
                <thead>
                    <tr>
                        <th>Quarter</th>
                        <th>Tests</th>
                        <th>Physicians</th>
                        <th>Coverage</th>
                        <th>Revenue</th>
                        <th>Key Milestone</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Q1 2028</strong></td>
                        <td>25,000</td>
                        <td>1,000</td>
                        <td>+2 LCDs, UHC</td>
                        <td>$6.25M</td>
                        <td>50,000th cumulative test</td>
                    </tr>
                    <tr>
                        <td><strong>Q2 2028</strong></td>
                        <td>35,000</td>
                        <td>1,500</td>
                        <td>+Anthem, Aetna</td>
                        <td>$8.75M</td>
                        <td>100,000th cumulative test</td>
                    </tr>
                    <tr>
                        <td><strong>Q3 2028</strong></td>
                        <td>42,000</td>
                        <td>1,900</td>
                        <td>+Cigna, Humana</td>
                        <td>$10.5M</td>
                        <td>NCD process initiated</td>
                    </tr>
                    <tr>
                        <td><strong>Q4 2028</strong></td>
                        <td>47,000</td>
                        <td>2,320</td>
                        <td>Near-national</td>
                        <td>$11.75M</td>
                        <td>200,000th cumulative test</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Year 2 Total</strong></td>
                        <td><strong>149,000</strong></td>
                        <td><strong>2,320</strong></td>
                        <td></td>
                        <td><strong>$37.3M</strong></td>
                        <td></td>
                    </tr>
                </tbody>
            </table>

            <h3>Critical Success Metrics (Dashboard)</h3>

            <h4>Weekly Tracking</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Year 1 Target</th>
                        <th>Year 2 Target</th>
                        <th>Why It Matters</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Tests processed this week</td>
                        <td>120 avg â†’ 450 by Q4</td>
                        <td>600 â†’ 900</td>
                        <td>Core volume metric</td>
                    </tr>
                    <tr>
                        <td>New physician activations</td>
                        <td>5-10/week</td>
                        <td>15-25/week</td>
                        <td>Growth engine</td>
                    </tr>
                    <tr>
                        <td>Repeat order rate</td>
                        <td>>60% by Q3</td>
                        <td>>75%</td>
                        <td>Physician retention</td>
                    </tr>
                    <tr>
                        <td>Sample rejection rate</td>
                        <td><3%</td>
                        <td><2%</td>
                        <td>Lab quality</td>
                    </tr>
                    <tr>
                        <td>Turnaround time (days)</td>
                        <td><10</td>
                        <td><7</td>
                        <td>Physician satisfaction</td>
                    </tr>
                    <tr>
                        <td>Net Promoter Score (physicians)</td>
                        <td>>40</td>
                        <td>>50</td>
                        <td>Leading indicator of growth</td>
                    </tr>
                </tbody>
            </table>

            <h4>Monthly Tracking</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Definition</th>
                        <th>Target</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Physician activation rate</td>
                        <td>% of contacted physicians who order at least 1 test</td>
                        <td>>25% Year 1; >35% Year 2</td>
                    </tr>
                    <tr>
                        <td>Average tests per active physician per month</td>
                        <td>Monthly ordering frequency</td>
                        <td>5+ (60+/year)</td>
                    </tr>
                    <tr>
                        <td>Physician churn rate</td>
                        <td>% who stop ordering in a given quarter</td>
                        <td><10% per quarter</td>
                    </tr>
                    <tr>
                        <td>Payer coverage win rate</td>
                        <td>% of payer submissions resulting in coverage</td>
                        <td>>70%</td>
                    </tr>
                    <tr>
                        <td>Revenue per test (effective)</td>
                        <td>Actual collected revenue divided by tests delivered</td>
                        <td>>$230</td>
                    </tr>
                    <tr>
                        <td>Customer acquisition cost (per physician)</td>
                        <td>Total sales/marketing cost divided by new ordering physicians</td>
                        <td><$1,500 Year 1; <$800 Year 2</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <!-- Section 7: Capital Requirements & Cash Flow -->
        <div class="section">
            <h2>7. Capital Requirements & Cash Flow</h2>

            <h3>Funding Phases</h3>

            <h4>Phase 1: Pre-Launch and CLIA Certification â€” $1.68M</h4>
            <table>
                <thead>
                    <tr>
                        <th>Category</th>
                        <th>Amount</th>
                        <th>Timeline</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>FDA Validation Study</td>
                        <td>$950K</td>
                        <td>Q1 2026 - Q1 2027</td>
                    </tr>
                    <tr>
                        <td>Lab Buildout + CLIA Certification</td>
                        <td>$517K</td>
                        <td>Q1 2026 - Q1 2027</td>
                    </tr>
                    <tr>
                        <td>Reimbursement Strategy Consultant</td>
                        <td>$125K</td>
                        <td>Q3 2026 - Q2 2027</td>
                    </tr>
                    <tr>
                        <td>Launch Marketing Materials</td>
                        <td>$50K</td>
                        <td>Q4 2026</td>
                    </tr>
                    <tr>
                        <td>Working Capital Reserve</td>
                        <td>$38K</td>
                        <td>Buffer</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total Phase 1</strong></td>
                        <td><strong>$1.68M</strong></td>
                        <td><strong>Seed/Pre-Seed</strong></td>
                    </tr>
                </tbody>
            </table>

            <h4>Phase 2: Year 1 Operations â€” $4.2M</h4>
            <table>
                <thead>
                    <tr>
                        <th>Category</th>
                        <th>Amount</th>
                        <th>Timeline</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Lab Operating Costs</td>
                        <td>$1.2M</td>
                        <td>Q1-Q4 2027</td>
                    </tr>
                    <tr>
                        <td>Commercial Team Compensation</td>
                        <td>$715K</td>
                        <td>Q1-Q4 2027</td>
                    </tr>
                    <tr>
                        <td>Marketing and Conference Budget</td>
                        <td>$350K</td>
                        <td>Q1-Q4 2027</td>
                    </tr>
                    <tr>
                        <td>Reimbursement Strategy (ongoing)</td>
                        <td>$200K</td>
                        <td>Q1-Q4 2027</td>
                    </tr>
                    <tr>
                        <td>G&A (legal, accounting, insurance, IT)</td>
                        <td>$500K</td>
                        <td>Q1-Q4 2027</td>
                    </tr>
                    <tr>
                        <td>Sample Collection Kits and Logistics</td>
                        <td>$300K</td>
                        <td>Q1-Q4 2027</td>
                    </tr>
                    <tr>
                        <td>IT Infrastructure (LIMS, ordering portal, EHR)</td>
                        <td>$250K</td>
                        <td>Q1-Q2 2027</td>
                    </tr>
                    <tr>
                        <td>Working Capital</td>
                        <td>$685K</td>
                        <td>Buffer for delayed collections</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total Phase 2</strong></td>
                        <td><strong>$4.2M</strong></td>
                        <td><strong>Seed Extension or Series A</strong></td>
                    </tr>
                </tbody>
            </table>

            <div class="success-box">
                <h4>Phase 2 Funding Note</h4>
                <p>Year 1 revenue is projected at $7.5M (base case). Even with delayed collections and ramp timing, the business should generate $4-5M in cash receipts during Year 1. This means Phase 2 funding of $4.2M provides sufficient runway even if revenue comes in 30-40% below projections.</p>
            </div>

            <h4>Phase 3: Year 2 Scaling â€” $8.5M</h4>
            <table>
                <thead>
                    <tr>
                        <th>Category</th>
                        <th>Amount</th>
                        <th>Timeline</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Lab Expansion (2nd instrument, staff, facility)</td>
                        <td>$3.0M</td>
                        <td>Q1-Q4 2028</td>
                    </tr>
                    <tr>
                        <td>Commercial Team Expansion (13 FTEs)</td>
                        <td>$1.82M</td>
                        <td>Q1-Q4 2028</td>
                    </tr>
                    <tr>
                        <td>Marketing and Brand Building</td>
                        <td>$800K</td>
                        <td>Q1-Q4 2028</td>
                    </tr>
                    <tr>
                        <td>Payer Relations and Reimbursement</td>
                        <td>$400K</td>
                        <td>Q1-Q4 2028</td>
                    </tr>
                    <tr>
                        <td>G&A Expansion</td>
                        <td>$800K</td>
                        <td>Q1-Q4 2028</td>
                    </tr>
                    <tr>
                        <td>IT/Data Infrastructure</td>
                        <td>$500K</td>
                        <td>Q1-Q4 2028</td>
                    </tr>
                    <tr>
                        <td>Sample Logistics Scaling</td>
                        <td>$600K</td>
                        <td>Q1-Q4 2028</td>
                    </tr>
                    <tr>
                        <td>Working Capital</td>
                        <td>$580K</td>
                        <td>Buffer</td>
                    </tr>
                    <tr style="background-color: #dbeafe; font-weight: 700;">
                        <td><strong>Total Phase 3</strong></td>
                        <td><strong>$8.5M</strong></td>
                        <td><strong>Series A</strong></td>
                    </tr>
                </tbody>
            </table>

            <div class="success-box">
                <h4>Phase 3 Funding Note</h4>
                <p>Year 2 revenue is projected at $37.3M. The business should become cash-flow positive during Year 2, reducing the actual external capital required. Phase 3 funding provides growth capital and working capital cushion, not survival capital.</p>
            </div>

            <h3>Cash Flow Projections</h3>
            <table>
                <thead>
                    <tr>
                        <th>Year</th>
                        <th>Revenue</th>
                        <th>Total Operating Costs</th>
                        <th>EBITDA</th>
                        <th>Cumulative Cash Position</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Pre-Launch</strong></td>
                        <td>$0</td>
                        <td>$1.68M</td>
                        <td>-$1.68M</td>
                        <td>-$1.68M (funded by seed)</td>
                    </tr>
                    <tr style="background-color: #d1fae5;">
                        <td><strong>Year 1 (2027)</strong></td>
                        <td>$7.5M</td>
                        <td>$4.2M</td>
                        <td><strong>+$3.3M</strong></td>
                        <td><strong>+$1.62M</strong></td>
                    </tr>
                    <tr style="background-color: #d1fae5;">
                        <td><strong>Year 2 (2028)</strong></td>
                        <td>$37.3M</td>
                        <td>$12.5M</td>
                        <td><strong>+$24.8M</strong></td>
                        <td><strong>+$26.4M</strong></td>
                    </tr>
                    <tr style="background-color: #d1fae5;">
                        <td><strong>Year 3 (2029)</strong></td>
                        <td>$112.0M</td>
                        <td>$28.0M</td>
                        <td><strong>+$84.0M</strong></td>
                        <td><strong>+$110.4M</strong></td>
                    </tr>
                    <tr style="background-color: #d1fae5;">
                        <td><strong>Year 4 (2030)</strong></td>
                        <td>$235.0M</td>
                        <td>$52.0M</td>
                        <td><strong>+$183.0M</strong></td>
                        <td><strong>+$293.4M</strong></td>
                    </tr>
                    <tr style="background-color: #d1fae5;">
                        <td><strong>Year 5 (2031)</strong></td>
                        <td>$380.0M</td>
                        <td>$78.0M</td>
                        <td><strong>+$302.0M</strong></td>
                        <td><strong>+$595.4M</strong></td>
                    </tr>
                </tbody>
            </table>

            <h3>Margin Structure at Scale</h3>
            <table>
                <thead>
                    <tr>
                        <th>Cost Category</th>
                        <th>Year 1 (% Rev)</th>
                        <th>Year 3 (% Rev)</th>
                        <th>Year 5 (% Rev)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Cost of Goods (lab reagents, supplies)</td>
                        <td>12%</td>
                        <td>8%</td>
                        <td>6%</td>
                    </tr>
                    <tr>
                        <td>Lab Personnel</td>
                        <td>8%</td>
                        <td>3%</td>
                        <td>2%</td>
                    </tr>
                    <tr>
                        <td>Lab Facility + Equipment</td>
                        <td>5%</td>
                        <td>1.5%</td>
                        <td>1%</td>
                    </tr>
                    <tr>
                        <td>Sales & Marketing</td>
                        <td>14%</td>
                        <td>5%</td>
                        <td>4%</td>
                    </tr>
                    <tr>
                        <td>G&A</td>
                        <td>7%</td>
                        <td>3%</td>
                        <td>2%</td>
                    </tr>
                    <tr>
                        <td>Reimbursement/Payer Relations</td>
                        <td>3%</td>
                        <td>0.5%</td>
                        <td>0.3%</td>
                    </tr>
                    <tr>
                        <td>IT/Infrastructure</td>
                        <td>3%</td>
                        <td>1%</td>
                        <td>0.5%</td>
                    </tr>
                    <tr>
                        <td>Sample Logistics</td>
                        <td>4%</td>
                        <td>2%</td>
                        <td>1.5%</td>
                    </tr>
                    <tr style="background-color: #fef3c7; font-weight: 700;">
                        <td><strong>Total Operating Costs</strong></td>
                        <td><strong>56%</strong></td>
                        <td><strong>24%</strong></td>
                        <td><strong>17%</strong></td>
                    </tr>
                    <tr style="background-color: #d1fae5; font-weight: 700;">
                        <td><strong>EBITDA Margin</strong></td>
                        <td><strong>44%</strong></td>
                        <td><strong>76%</strong></td>
                        <td><strong>83%</strong></td>
                    </tr>
                </tbody>
            </table>

            <div class="success-box">
                <h4>Key Insight for Investors</h4>
                <p>Diagnostic tests have among the highest margins in healthcare. The cost of running a blood test does not increase proportionally with volume. Lab reagent costs are approximately $15-25 per test regardless of volume, and fixed costs (facility, equipment, personnel) are spread across increasing volumes.</p>
                <p style="margin-top: 10px;"><strong>This creates dramatic margin expansion as scale increases â€” from 44% EBITDA margin in Year 1 to 83% by Year 5.</strong></p>
            </div>

            <h3>Cash-Flow Positive Timeline</h3>
            <table>
                <thead>
                    <tr>
                        <th>Milestone</th>
                        <th>Timing</th>
                        <th>Significance</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>First revenue</td>
                        <td>Q1 2027</td>
                        <td>Proof of commercial viability</td>
                    </tr>
                    <tr style="background-color: #d1fae5;">
                        <td><strong>Monthly cash-flow positive</strong></td>
                        <td><strong>Q3-Q4 2027</strong></td>
                        <td><strong>Monthly revenue exceeds monthly costs</strong></td>
                    </tr>
                    <tr style="background-color: #d1fae5;">
                        <td><strong>Cumulative cash-flow positive</strong></td>
                        <td><strong>Q1-Q2 2028</strong></td>
                        <td><strong>Total revenue exceeds total invested capital</strong></td>
                    </tr>
                    <tr>
                        <td>Annual EBITDA >$20M</td>
                        <td>Year 2 (2028)</td>
                        <td>Demonstrates profitability at scale</td>
                    </tr>
                    <tr>
                        <td>Annual EBITDA >$80M</td>
                        <td>Year 3 (2029)</td>
                        <td>Validates category-defining business</td>
                    </tr>
                </tbody>
            </table>

            <div class="success-box">
                <h4>Exceptional Time to Profitability</h4>
                <p>The business reaches cumulative cash-flow positive within 12-18 months of launch. This is exceptionally fast for a diagnostic company and reflects the capital-efficient CLIA LDT model versus the capital-intensive pharma development model.</p>
            </div>
        </div>

        <!-- Summary Stats -->
        <div class="stat-grid">
            <div class="stat-card">
                <div class="stat-value">$772M</div>
                <div class="stat-label">5-Year Revenue (Base Case)</div>
            </div>
            <div class="stat-card">
                <div class="stat-value">20,700</div>
                <div class="stat-label">Ordering Physicians by Year 5</div>
            </div>
            <div class="stat-card">
                <div class="stat-value">83%</div>
                <div class="stat-label">EBITDA Margin (Year 5)</div>
            </div>
            <div class="stat-card">
                <div class="stat-value">6-9 mo</div>
                <div class="stat-label">Time to Cash-Flow Positive</div>
            </div>
        </div>

        <div class="footer">
            <p><strong>Document Prepared For:</strong> A1 Diagnosis Investor Relations</p>
            <p><strong>Document Date:</strong> January 2026</p>
            <p style="margin-top: 15px;"><strong>Confidential:</strong> This document contains proprietary and confidential information. Not for distribution.</p>
        </div>
    </div>
</body>
</html>